

## Recombinant Human IL-32 alpha protein(His Tag)

Catalog Number: PKSH034116

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.

### Description

<b>Species</b>	Human
<b>Source</b>	E.coli-derived Human IL-32 alpha protein Met 1-Lys 131, with an C-terminal His
<b>Calculated MW</b>	15.7 kDa
<b>Observed MW</b>	18 kDa
<b>Accession</b>	P24001-4
<b>Bio-activity</b>	Measure by its ability to induce TNF alpha secretion in RAW264.7 cells. The ED <sub>50</sub> for this effect is <10 µg/mL.

### Properties

<b>Purity</b>	> 98 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 0.1 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 8.0. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Background

IL-32 is a recently discovered cytokine that induces various proinflammatory cytokines (TNF-alpha, IL-1beta, IL-6) and chemokines in both human and mouse cells through the NF-kappaB and p38 MAPK inflammatory signal pathways. It is regulated robustly by other major proinflammatory cytokines and is crucial to inflammation and immune responses. Four of the IL-32 isoforms (alpha, beta, gamma, and delta) are the most representative IL-32 transcripts, and the gamma isoform of IL-32 is the most active, although all isoforms are biologically active. IL-32, a cytokine produced mainly by T, natural killer, and epithelial cells induces significant amounts of TNFalpha and MIP-2 and increases the production of both cytokines in a dose-dependent manner. IL-32 has been implicated in inflammatory disorders, Mycobacterium tuberculosis infections, inflammatory bowel disease, and influenza A virus infection, as well as in some autoimmune diseases, such as rheumatoid arthritis, ulcerative colitis, and in the human stomach cancer, human lung cancer, and breast cancer tissues. Thus, IL-32 expression might be valuable as a biomarker for cancer.